comunicacio

Catalonia promotes the first public bank of fecal microbiota in Spain to treat some serious intestinal infections

The Microbiota Bank of Catalonia, a pioneering initiative in the public sphere that positions the Catalan health system as a benchmark in the therapeutic use of faecal microbiota has been launched.

Catalonia promotes the first public bank of fecal microbiota in Spain to treat some serious intestinal infections Read More »

A study led by Bellvitge points out that fosfomycin can improve the treatment of bacteremia caused by S. aureus

Combining fosfomycin with other antibiotics can help eliminate the infection more quickly, however, is also associated with an increase in side effects.

A study led by Bellvitge points out that fosfomycin can improve the treatment of bacteremia caused by S. aureus Read More »

A Bellvitge study analyzes the clinical impact of amoxicillin resistance on invasive pneumococcal pneumonia

According to the results, amoxicillin may be associated with a less favourable clinical outcome, especially in cases with resistant strains and in people with a worse initial prognosis.

A Bellvitge study analyzes the clinical impact of amoxicillin resistance on invasive pneumococcal pneumonia Read More »

A study by the UB and IDIBELL identifies a key neurophysiological mechanism in the formation of memories in humans

A team from the Faculty of Psychology of the University of Barcelona (UB), the Institute of Neurosciences of the UB (UBNeuro) and the Bellvitge Biomedical Research Institute (IDIBELL) has identified for the first time in humans, and in a realistic environment, a key neurophysiological mechanism in memory formation: brain waves type Ripple, high-frequency electrical oscillations,

A study by the UB and IDIBELL identifies a key neurophysiological mechanism in the formation of memories in humans Read More »

Bellvitge leads the first clinical trial to evaluate antifibrotic benefit in patients with post-COVID fibrosis

The study confirms the improvement in severe lung affectation after COVID-19 thanks to the combination of pirfenidone and corticosteroids.

Bellvitge leads the first clinical trial to evaluate antifibrotic benefit in patients with post-COVID fibrosis Read More »

Scroll to Top